不同方法应用促红细胞生成素治疗肾性贫血临床观察  

Clinical Study on Different Application Methods of Recombinant Human Erythropoietin in the Treatment of Renal Anemia

作　　者：任丽雯[1] 黄蔚霞[1] 董飞侠[1] 陈念昭[1] 陈宇[1] 

机构地区：[1]浙江中医药大学附属温州市中医院,浙江温州325000

出　　处：《中国药师》2014年第3期435-438,共4页China Pharmacist

摘　　要：目的:评价不同方法应用促红细胞生成素治疗肾性贫血的有效性和安全性。方法:165例慢性肾功能衰竭合并肾性贫血患者随机进入试验组及对照组,观察组给予促红细胞生成素(EP0)10 000 IU皮下注射,每周1次,对照组3 000 IU皮下注射,每周3次,并视病情改善情况适当减少剂量。在12周疗程内观察两组不良反应,监测血常规[血白蛋白(Hb),红细胞计数(RBC)]、红细胞压积(HCT)、肌酐(Scr)、尿素氮(BUN)、丙氨酸氨基转移酶等,比较两组EPO使用的总剂量、总费用及注射次数。结果:观察组74例、对照组76例完成12周的治疗观察。两组疗效比较差异无统计学意义(P>0.05)。两组治疗后的Hb、RBC、HCT均较治疗前明显升高,而两组Scr及BUN则较治疗前明显降低(P<0.01)。治疗后两组Hb、RBC、HCT、Scr、BUN,以及不良反应发生率比较,差异均无统计学意义(P>0.05)。观察组EPO总剂量、总注射次数、总费用明显少于对照组(P<0.05或0.01)。结论:与常规3 000IU皮下注射EPO比较,10 000 IU皮下注射EPO在较好地纠正肾性贫血的同时,又能减少慢性肾功能衰竭合并肾性贫血的针刺痛苦和经济负担,且不良反应无明显增多。Objective： To evaluate the efficacy and safety of different application methods of recombinant human erythropoietin erythropoietin （EPO）in the treatment of renal anemia. Methods： Totally 165 patients with renal anemia caused by chronic renal failure were randomly divided into the test group and the control group. The patients in the test group were subcutaneously injected 10000 units of EPO once a week, while those in the control group were given 3000 units of EPO three times a week, and the dosage was reduced according to the efficacy. During the course of 12-week treatment, the adverse reactions, blood routine, hematocrit and functions of re- nal and liver were monitored. The total dose, expense and injection times in the two groups were calculated and compared. Results： There were 74 patients in the test group and 76 in the control group were finished the 12-week treatment. The efficacy was no signifi- cant difference between the two groups（P 〉 0.05 ）. After the 12-week treatment, Hb, RBC and HCT increased significantly and Scr and BUN decreased significantly compared with the baseline in both groups（P 〈0.01 ） , and Hb, RBC, HCT, Scr, BUN and the ad- verse reactions were no significant difference between the two groups（ P 〉 0.05 ）. The total dose, expense and injection times in the test group were significant lower than those in the control group（ P 〈 0.05, P 〈 0.01,P 〈 0.01, respectively）. Conclusion： Compared with the routine dose of EPO, large dose of EPO can effectively treat renal anemia with reduced injection distress, expense and adverse reactions.

关 键 词：慢性肾功能衰竭 肾性贫血 促红细胞生成素 应用方法 

分 类 号：R973.3[医药卫生—药品]